# Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07408089/  
OnCo record `nct07408089` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BBI-940 run by Boundless Bio, Inc., terminated.

## Summary

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer is a phase 1 interventional study registered as NCT07408089 by Boundless Bio, Inc., with 8 participants enrolled, started 2026-02-25. Conditions recorded: Breast Cancer, Metastatic Breast Cancer and Advanced Breast Cancer. Interventions recorded: BBI-940 and Fulvestrant.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07408089
- Phase: 1
- Setting: An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)
- Sponsor: Boundless Bio, Inc.
- Enrolled: 8

## Sources

- ClinicalTrials.gov NCT07408089: https://clinicaltrials.gov/study/NCT07408089

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [BBI-940](https://onco.cc/drugs/bbi-940/)
- companies: [Boundless Bio](https://onco.cc/companies/boundless-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct07408089.json